$OMER News
Last published 1d ago
- 1d agoOMEROmeros Corporation to Announce Third Quarter Financial Results on November 16, 2026Business WireSEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial ...
- 3w agoOMEROmeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMABusiness WireOmeros Corporation (NASDAQ:OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s marketing authorization
- 3mo agoOMEROmeros Corporation Q2 2026 Earnings Conference Call - OMEROS CORPEarnings Call TranscriptsGood afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode. After the company's remarks, we will conduct a question-and-answer session. If you wou
- 3mo agoOMEROmeros Corporation Reports Second Quarter 2026 Financial ResultsBusiness Wire– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which
- 3mo agoOMEROmeros Corporation to Announce Second Quarter Financial Results on August 12, 2026Business WireOmeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call
- 3mo agoOMERCMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®Business Wire--Provides additional Medicare reimbursement to hospitals and supports patient access for eligible Medicare patients with TA-TMA-- Omeros Corporation (NASDAQ:OMER) today announced that the Centers for Medicare &
- 4mo agoOMEROmeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMABusiness WireOmeros Corporation (NASDAQ:OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization
- 4mo agoOMEROMEROS CORPORATION ANNUAL MEETING OF SHAREHOLDERS - OMEROS CORPEarnings Call TranscriptsPlease stand by, we are about to begin. Hello and welcome to the annual meeting of shareholders of Omeris Corporation. Please note that today's meeting is being recorded. During the meeting, we'll have a question and ans
- 4mo agoOMEROMEROS CORPORATION Annual Meeting of Shareholders - OMEROS CORPEarnings Call TranscriptsPlease stand by, we are about to begin. Hello and welcome to the annual meeting of shareholders of Omeris Corporation. Please note that today's meeting is being recorded. During the meeting, we'll have a question and ans
- 4mo agoOMEROmeros Announces Webcast Details for Annual Meeting of ShareholdersBusiness WireOmeros Corporation (NASDAQ:OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 18, 2026, beginning at 10:00 a.m. Pacific
- 6mo agoOMEROmeros Corporation Reports First Quarter 2026 Financial ResultsBusiness Wire– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which
- 6mo agoOMEROmeros Corporation to Announce First Quarter Financial Results on May 13, 2026Business WireOmeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and
- 6mo agoOMERSGMTSagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerGlobeNewswireSAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
- 6mo agoOMERCMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)Business Wire– Permanent, product-specific J-code facilitates efficient claims and reimbursement – Omeros Corporation (NASDAQ:OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a
- 7mo agoOMEROmeros Corporation Reports Fourth Quarter and Year-End 2025 Financial ResultsBusiness Wire– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which
- 7mo agoOMEROmeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026Business WireOmeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will
- 7mo agoOMEROmeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA TreatmentBusiness WireOmeros Corporation (NASDAQ:OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm
- 8mo agoOMEROmeros Announces Successful Primate Study in OncotoX-AML™ Drug ProgramBusiness Wire— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — Omeros Corporation (NASDAQ:OMER) today announced the successful completion of its initial study in nonhuman
- 10mo agoOMEROmeros Announces New Date for YARTEMLEA® Approval Conference CallBusiness Wire— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of
- 10mo agoOMERFDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMABusiness Wire– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET – First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated
- 11mo agoOMEROmeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)Business WireOmeros Corporation (NASDAQ:OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a
- 12mo agoOMEROmeros Corporation Reports Third Quarter 2025 Financial ResultsBusiness Wire– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which
- 1y agoOMEROmeros Corporation to Announce Third Quarter Financial Results on November 13, 2025Business WireOmeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management
- 1y agoOMEROmeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control GroupBusiness WireOmeros Corporation (NASDAQ:OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with
- 1y agoOMERNovo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)GlobeNewswireZaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term
- 1y agoOMEROmeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access ProgramBusiness WireOmeros Corporation (NASDAQ:OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening
- 1y agoOMEROmeros Corporation (OMER) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoOMEROmeros Corporation Reports Second Quarter 2025 Financial ResultsBusiness Wire– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which
- 1y agoOMEROmeros Corporation to Announce Second Quarter Financial Results on August 14, 2025Business WireOmeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host
- 1y agoOMEROmeros Corporation Announces Pricing of $22 Million Registered Direct OfferingBusiness WireOmeros Corporation (NASDAQ:OMER) ("Omeros" or the "Company") announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its
- 1y agoOMEROmeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMABusiness WireOmeros Corporation (NASDAQ:OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell
- 1y agoOMEROmeros Announces Webcast Details for Annual Meeting of ShareholdersBusiness WireOmeros Corporation (NASDAQ:OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 27, 2025, starting at 10:00 a.m. Pacific
- 1y agoOMEROmeros Corporation Reports First Quarter 2025 Financial ResultsBusiness Wire– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: Net
- 1y agoOMEROmeros Corporation to Announce First Quarter Financial Results on May 15, 2025Business WireOmeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a
- 1y agoOMEROmeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026Business WireOmeros Corporation (NASDAQ:OMER) ("Omeros" or the "Company") today announced that it has entered into exchange agreements (the "Exchange Agreements") with a limited number of investors who are holders of the Company's
- 1y agoOMERFDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA DateBusiness WireOmeros Corporation (NASDAQ:OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of
- 1y agoOMEROmeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical ProgramBusiness Wire– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers – Omeros Corporation (NASDAQ:OMER) today announced the establishment of the
- 1y agoOMEROmeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious DiseasesBusiness Wire-- Targeted Complement Activating Therapy™ Represents Next-Generation, Broadly Applicable Antimicrobial Therapeutics – Omeros Corporation (NASDAQ:OMER) today announced that the first public presentation of its
- 1y agoOMEROmeros Corporation Reports Fourth Quarter and Year-End 2024 Financial ResultsBusiness Wire– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which
- 1y agoOMEROmeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025Business WireOmeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management
- 1y agoOMEROmeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial ProgramBusiness Wire-- Phase 3 Data Needed for BLA Submission Expected in the Fourth Quarter 2026 -- Omeros Corporation (NASDAQ:OMER) today reported that clinical trial site activation for enrollment is underway for the company's Phase 3
- 1y agoOMEROmeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company's OMS527 Program to Treat Cocaine Use DisorderBusiness Wire– Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase 1b Clinical Trial in Patients with CUD – Omeros Corporation (NASDAQ:OMER) today announced that it has received a funding commitment
- 1y agoOMEROmeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMABusiness Wire– Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, over External Control Patients – Results of
- 1y agoOMEROmeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem MeetingsBusiness WireOmeros Corporation (NASDAQ:OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the
- 1y agoOMEROmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access ProgramBusiness WireOmeros Corporation (NASDAQ:OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and
- 1y agoOMEROmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary EndpointBusiness Wire– Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA – Sensitivity analyses support the results of the primary
- 1y agoOMEROmeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMABusiness WirePrimary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an external control stem
- 1y agoOMEROmeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual MeetingBusiness Wire-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros' Zaltenibart Phase 3 Clinical Program in PNH -- Omeros Corporation (NASDAQ:OMER) today announced that two posters directed to
- 1y agoOMEROmeros Corporation Announces Upcoming Presentations at ASH Annual MeetingBusiness Wire-- Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart -- Omeros Corporation (NASDAQ:OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros'
- 1y agoOMEROmeros Corporation Provides Update on Progress Toward BLA ResubmissionBusiness WireOmeros Corporation (NASDAQ:OMER) today announced an update on its progress toward planned resubmission of its biologics license application ("BLA") for narsoplimab, the company's first-in-class antibody targeting